the actually EMD AML incidence is up for dispute as you...

the actually EMD AML incidence is up for dispute as you mentioned. why test when knowing if you have EMD AML has no SoC presently so you fall back into AML treatment basket.

Astex is perhaps hedging their bets as a collaborator for ASTX727 and Venetoclax R/R AML trial. Pharmacokinetics, Safety, and Efficacy of ASTX727 in Combination With Venetoclax in Acute Myeloid Leukemia (AML) - Full Text View - ClinicalTrials.gov

But per previous ASH publications showed not clinically significant, or borderline at best. Clinical and molecular predictors of response and survival following venetoclax therapy in relapsed/refractory AML | Blood Advances | American Society of Hematology (ashpublications.org)

Also, Zantrene shown in synergise in combo with ASTX727 and Venetoclax, so think Zantrene would still be a front running, but something worth keeping an eye on. MD Anderson Cancer Center Researchers Publish AML Preclinical Study on Zantrene® Drug Combinations – Race Oncology

So commercially I think Astex could get more market share by providing an EMD AML protect version of ASTX727, rather than just AML SoC.